Christophe Nicot, Kansas University Medical Center, USA
Call for papers
- Aging and Cellular Fate: Senescence, Death, or Cancer
- Latest Correspondence on Biomarkers for Cancer diagnosis, prognosis, and drug resistance
- Phase 2 and 3 studies
- Molecular understanding and clinical aspects of immunotherapy in the treatment of cancer
Molecular Cancer invites submissions to this article collection. This Collection aims to unravel complex interplay between cellular aging processes, such as senescence and apoptosis, and their impact on cancer initiation, progression, and therapeutic responses. The collection is open to submissions till 31st December 2023.
Molecular Cancer is calling for submissions to our Collection on 'Latest Correspondence on Biomarkers for Cancer diagnosis, prognosis, and drug resistance.' We welcome Correspondences that address this multifaceted role of biomarkers in guiding personalized treatment strategies, improving patient outcomes, and advancing our understanding of cancer biology. The collection is open to submissions till 31st July 2024.
Molecular Cancer invites submissions to this article collection. Topics of interest include original reports on human clinical trials phase 2 and phase 3 as well as reviews of recently reported clinical trials. The collection also invites authors to submit research article or correspondence related to clinical biomarkers of disease progression and/or resistance to commonly used therapies. The collection is open to submissions till October 15th 2023.
Molecular Cancer invites submissions to this article collection. Topics of interest include, but are not limited to, adoptive cellular immunotherapy, chimeric antigen receptor T-cell (CAR-T) immunotherapy, immune checkpoint inhibitors, modulators of tumor microenvironment, and drug resistance mechanisms in immunotherapy. The collection is open to submissions from August 15th 2022 to September 15th 2023.
2022 Special Issues
- Liquid Biopsy at the Frontier of Early Detection, Prognosis and Cancer Treatments
- Genome Editing and the Future of Personalized and Targeted Cancer Medicine
This special issue published by Molecular Cancer focuses on the clinical aspects of liquid biopsies, in particular validation of novel biomarkers that may serve as signature for non-invasive early detection of cancerous cells, predict patients' risks of disease progression and response to specific therapies.
Molecular Cancer is excited to present a series of original research and review articles related to genome editing and reprogramming.
Aims and scope
Molecular Cancer is an open access, peer-reviewed journal interested in attracting high-quality original research and reviews that present or highlight significant advances in all areas of cancer and related biomedical science.
2021 Thematic Series: mRNA therapies and mRNA vaccines in cancer
In this review, Sahebkar et al. summarize the current knowledge on the contribution of the NLRP3 inflammasome on potential cancer promotion and therapy.
The Chinese American Hematologist and Oncologist Network (CAHON) has published an important and timely Editorial in the Journal of Hematology & Oncology. Molecular Cancer is proud to stand with them in denouncing in the strongest terms all forms of discrimination and crimes against any racial/ethnic group, including Asian Americans and Pacific Islanders, and to call on our readers to pursue racial equality and tolerance in the USA and beyond.
Recognising Editorial Excellence
Molecular Cancer is a top rated Springer Nature journal. Prof. Christophe Nicot and the editorial team performed in the top percentile of journals based on data collected from the Journal Author Satisfaction Survey. We are recognising extraordinary editors for their commitment and passion to their journals. Read more about editorial excellence here.
What is trending?
Click here to see which articles published in Microbiome have been shared the most in 2021.
Springer Nature Oncology Portfolio
Discover the range of academic oncology titles at Springer Nature here.
Annual Journal Metrics
2022 Citation Impact
37.3 - 2-year Impact Factor
33.1 - 5-year Impact Factor
5.740 - SNIP (Source Normalized Impact per Paper)
8.703 - SJR (SCImago Journal Rank)
4 days submission to first editorial decision for all manuscripts (Median)
76 days submission to accept (Median)
4,920 Altmetric mentions